MAP3K8/Tpl2/COT Antibody (634130) [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: WB
• Clone: 634130
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

MAP3K8/Tpl2/COT Antibody (634130) [Alexa Fluor® 532] Summary

• Immunogen: E. coli-derived recombinant human MAP3K8/Tpl2/COT
  Gln173-Gln395
  Accession # P41279
• Specificity: Detects human MAP3K8/Tpl2/COT in direct ELISAs and Western blots.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MAP3K8/Tpl2/COT Antibody (634130) [Alexa Fluor® 532]

• Cancer Osaka thyroid oncogene
• c-COT
• cot (cancer Osaka thyroid) oncogene
• COT
• COTMEKK8
• EC 2.7.11.25
• EST
• ESTF
• ESTFLJ10486
• Ewing sarcoma transformant
• MAP3K8
• mitogen-activated protein kinase kinase kinase 8
• Proto-oncogene c-Cot
• proto-oncogene serine/threoine protein kinase
• Serine/threonine-protein kinase cot
• TPL2
• Tpl-2
• Tumor progression locus 2
• tumor progression locus-2

Background

MAP3K8, also called Tpl2 (tumor progression locus 2) or COT (Cancer Osaka Thyroid oncogene) is a cytosolic Ser/Thr kinase. MAP3K8 is one of the MAP kinase kinase (MAPKK) kinases that regulates the ERK1/ERK2 pathway in response to IL-1, facilitating IL-8 and MIP-1 beta production. MAP3K8 activates I kappa B kinases and induces the nuclear production of NF-kappa B. Human MAP3K8 shares 97% and 98% amino acid (aa) identity with mouse and rat MAP3K8, respectively, within the region used as an immunogen. Alternative start sites can give a 58 kDa (467 aa) isoform with stronger activity but shorter half-life than a 52 kDa (397 aa) isoform.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.